Everolimus - redOrbit

PROMUS Element(TM) Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study

2012-05-17 22:21:30

NATICK, Mass., May 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness

OrbusNeich's Combo Dual Therapy Stent(TM) Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up

2012-05-15 10:24:43

Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stE

One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY(TM) Stent Versus PROMUS Element(TM) Platinum Chromium Stent

2012-05-15 06:29:45

NATICK, Mass., May 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer-Coated

Abbott's XIENCE PRIME(TM) and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

2012-05-15 02:29:10

PARIS, May 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the XIENCE PRIME(TM) and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received

Boston Scientific Announces Schedule For EuroPCR 2012

2012-05-10 02:31:58

NATICK, Mass., May 10, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces its schedule of major events and sponsored clinical research at the annual

News - Everolimus

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health